Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mapaex consumer healthcare (ireland) private limited, Írsko - flurbiprofén - 69 - otorhinolaryngologica

Европейский союз - словацкий - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Европейский союз - словацкий - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate disodný, glycopyrronium bromid - pľúcna choroba, chronická obštrukcia - drogy obštrukčnej choroby dýchacích ciest, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Европейский союз - словацкий - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - liečivá na dermatitídu okrem kortikosteroidov - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

b.braun melsungen ag, nemecko - aminokyseliny - 76 - infundibilia

Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

b.braun melsungen ag, nemecko - kombinácie - 76 - infundibilia

Европейский союз - словацкий - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastické činidlá - prsia cancerdocetaxel kabi v kombinácii s doxorubicin a cyklofosfamidom je indikovaný na adjuvantnej liečby u pacientov s:funkčnom uzol-pozitívnou rakovinou prsníka;funkčnom uzol-negatívne rakovine prsníka. pre pacientov s funkčnom uzol-negatívne rakoviny prsníka, adjuvantná liečba by mala byť obmedzená na pacientov oprávnené prijímať chemoterapia podľa medzinárodne stanovených kritérií pre primárnej liečbe včasného karcinómu prsníka. docetaxel kabi v kombinácii s doxorubicin je indikovaný na liečbu pacientov s lokálne pokročilého alebo metastatického karcinómu prsníka, ktorí sa v minulosti nedostali cytotoxické terapia pre tento stav. docetaxel kabi monotherapy je indikovaný na liečbu pacientov s lokálne pokročilého alebo metastatického karcinómu prsníka po zlyhaní cytotoxické terapia. predchádzajúca chemoterapia mala zahŕňať antracyklín alebo alkylačné činidlo. docetaxel kabi v kombinácii s trastuzumab je indikovaný na liečbu pacientov s metastatickým rakoviny prsníka, ktorých nádory overexpress her2 a ktoré sa predtým nedostali chemoterapii pre metastatické ochorenie. docetaxel kabi v kombinácii s capecitabine je indikovaný na liečbu pacientov s lokálne pokročilého alebo metastatického karcinómu prsníka po zlyhaní cytotoxické chemoterapia. predchádzajúca liečba mala zahŕňať antracyklín. non-small cell lung cancerdocetaxel kabi je indikovaný na liečbu pacientov s lokálne pokročilým alebo metastatickým non-small-bunky rakoviny pľúc po zlyhaní predchádzajúcej chemoterapie. docetaxel kabi v kombinácii s cisplatin je indikovaný na liečbu pacientov s unresectable, lokálne pokročilým alebo metastatickým non-small cell lung cancer, u pacientov, ktorí v minulosti boli liečení chemoterapiou, táto podmienka. prostate cancerdocetaxel kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer. docetaxel kabi v kombinácii s androgén-deprivácie terapia (pdo), s alebo bez prednizón alebo prednisolone, je indikovaný na liečbu pacientov s metastatickým hormón-citlivé rakoviny prostaty. Žalúdočné adenocarcinomadocetaxel kabi v kombinácii s cisplatin a 5-fluorouracil je indikovaný na liečbu pacientov s metastatickým žalúdočnej adenocarcinoma, vrátane adenocarcinoma z gastroezofageálny križovatke, ktorí nedostali pred chemoterapii pre metastatické ochorenie. hlavy a krku cancerdocetaxel kabi v kombinácii s cisplatin a 5-fluorouracil je indikovaný na indukčnú liečbu pacientov s lokálne pokročilým karcinómom bunky karcinómu hlavy a krku.

Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

b.braun melsungen ag, nemecko - aminokyseliny - 47 - diaetetica

Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fresenius kabi ab, Švédsko - aminokyseliny - 76 - infundibilia

Словакия - словацкий - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fresenius kabi s.r.o., Česká republika - aminokyseliny - 76 - infundibilia